AB Science

Paris, Ile-de-France, France · Biotechnology · 135 employees

AB Science S.A. is a biopharmaceutical company specializing in the research and development of innovative therapies for various diseases. The company is focused on providing solutions for serious medical conditions, primarily in oncology and neurodegenerative disorders. AB Science's lead program, AB8939, is aimed at treating acute myeloid leukemia (AML). With strong financial backing, the company

Funding history

Post-IPO Equity — $2.8M — Oct 2025

Recent signals

Oct 17, 2025: Raised $2.8M in Post-IPO Equity

See plans & pricing → Track AB Science’s funding, hiring, and signals — with verified contacts — on Fundz.